The UK Collaborative HIV Cohort (UK CHIC) Study

Slides:



Advertisements
Similar presentations
Grid Security/Edinburgh 5 th & 6 th December 2002 Confidentiality, Consent & Access Peter Singleton - Cambridge Health Informatics.
Advertisements

Key messages Antiretroviral therapy (ART) has transformed treatment of HIV infection The benefits of early diagnosis of HIV are well recognised - not offering.
Estimating the number of Kentuckians living with HIV disease with unmet needs for HIV-related primary care in calendar year 2010  Reducing new HIV infections.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
BHIVA national clinical audit of HIV diagnosis Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
NDAU/NNAP Collaborators Meeting A National Neonatal Network Neena Modi Professor of Neonatal Medicine Imperial College London Vice President, Science &
NDAU/NNAP Collaborators Meeting Neena Modi Professor of Neonatal Medicine Imperial College London Vice President, Science & Research Royal College of Paediatrics.
UK HIV Drug Resistance Database. Background (1) HIV drug resistance testing first became available in UK in At least 10 laboratories currently.
HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,
Proposed study on HIV and ageing As HIV mortality rates have dropped, an increasing proportion of individuals are living with HIV to older ages As HIV.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.
April 2, 2013 Longitudinal Data system Governance: Status Report Alan Phillips Deputy Director, Fiscal Affairs, Budgeting and IT Illinois Board of Higher.
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Texas Medical Monitoring Project (MMP) Meeting Omni Austin Hotel at Southpark Thursday, May 31, 2007 a multi-stage probability sample of HIV infected adults.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
HIV and ageing: study aims Aim: to examine the effects of ageing on medical and social outcomes of people living with HIV Example research questions: -
The UK HIV Drug Resistance Database: Development and use for national surveillance BACKGROUND Deenan Pillay 1 and Hannah Green 2 on behalf of the UK Collaborative.
Temporal patterns in the rate of transmitted resistance in the UK BACKGROUND Hannah Green 1, Anton Pozniak 2 and Kholoud Porter 1 on behalf of the UK Collaborative.
Techniques for Data Linkage and Anonymisation – A Funders View Turing Gateway Meeting 23 rd October 2014 Dr Mark Pitman.
C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.
BHIVA Audit Survey of patient assessment and monitoring Set-up phase of cohort audit of patients starting ART from naïve.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System RITA as part of routine national HIV surveillance: Experience.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
CONCLUSIONS  Mortality and hospital admission rates continued to decline since the introduction of HAART in 1997  Viral load suppression 12 months after.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
The case for HIV testing A presentation for the clinical team in your practice.
Access to data for local authority public health AGW Public Health Network Training Event: Public Health Data, Information and Intelligence 11 th November.
Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,
© National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. All rights reserved. Not to be reproduced in whole or in part.
Lisa S BURCH, Natasha OAKES-MONGER, Colette J SMITH, Fiona C LAMPE, Rob TSINTAS, Clinton CHALONER, Anderw N PHILLIPS, Margaret A JOHNSON Research Department.
UKCHIC Richard Gilson on behalf of the Hepatitis Subgroup Progress update July 2010 UK CHIC.
The Research Question What factors characterize the elite successes among HAART recipients in a NYC HIV care clinic?
Atazanavir Use in Pregnancy : a report of 33 cases St George’s Hospital South West London HIV & GUM Clinical Services Network Macky Natha 1, Phillip Hay.
Socio-economic factors and late diagnosis of HIV in in the Royal Free cohort Socio-economic factors and late diagnosis of HIV in in.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
RaDaR – a national web based data collection for rare kidney diseases Moin Saleem – University of Bristol Mark Taylor – Birmingham Children’s Hospital.
Exposure and response to highly active antiretroviral therapy (HAART) in ART naïve children in the UK and Ireland Judd A. 1, Lee K.J. 1, Duong T. 1, Walker.
Mental health diagnoses in HIV infected young people: a HIV in Young People Network audit Dr Ellen Dwyer 1 Dr Caroline Foster 2 Dr Katia Prime 3 1 Croydon.
Realising MRC’s Vision in Health and Bioinformatics MRC Open Council Meeting July 2014 Janet Valentine Head of Population Health and Informatics.
Malignancies in Young People Sophie Herbert, Alison Barbour, Eva Jungmann, Caroline Foster on behalf of the HIV Young Persons Network (HYPNET)
People living with HIV can inform design of cure research: an online international survey Julie Fox.
Patients with perinatal HIV transitioning to adult care
Utilizing research as an opportunity to strengthen
1UCL, London, UK; 2Barts Health NHS Trust
Poster P200 18th Annual Conference of the British HIV Association (BHIVA), 18 – 20th April 2012, Birmingham, UK An analysis of the reasons for switching.
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Mortality and cause of death among HIV patients in London in 2016
Volume 5, Issue 6, Pages e301-e308 (June 2018)
Presentation transcript:

The UK Collaborative HIV Cohort (UK CHIC) Study

Background Information on HIV infection in the UK comes from a variety of sources; these are often limited in scope Many clinical centres routinely collect information about HIV-positive patients when they attend: This provides an ideal opportunity to study HIV-positive individuals in their clinical setting. Existing infrastructure can be used for data collection. Patients from a wide variety of clinics are included so that the cohort becomes more representative of HIV-positive people in the UK.

UK CHIC: Objectives UK CHIC initiated in 2001 to collate routinely collected data from HIV-positive patients attending some of the largest clinical centres in the UK since 1st January 1996 Specific aims are: to describe the characteristics of patients with HIV under care to provide information on exposure to combination antiretroviral therapy (cART) and changes to the immunological, virological and clinical status of patients over time to monitor the frequency of AIDS and survival over time.

UK CHIC: Participating clinics Clinical centres Brighton and Sussex University Hospitals NHS Trust York Teaching Hospital NHS Foundation Trust Chelsea & Westminster NHS Trust Coventry, University Hospitals Coventry and Warwickshire NHS Trust Mortimer Market Centre, Central and NW London NHS Foundation Trust Wolverhampton, The Royal Wolverhampton NHS Trust Kings College Hospital NHS Trust Chertsey, Ashford and St Peter’s Hospitals NHS Foundation Trust Royal Free NHS Trust St Mary’s, Imperial College Healthcare NHS Trust Barts and the London NHS Trust Homerton University Hospital NHS Trust Edinburgh, The Lothian University Hospitals NHS Trust North Middlesex University Hospital NHS Trust Collaborators North Bristol NHS Trust Research Dept. of Infection and Population Health, UCL Leicester, University Hospitals of Leicester NHS Trust Medical Research Council Clinical Trials Unit at UCL Middlesbrough, South Tees Hospitals NHS Foundation Trust Public Health England (formerly HPA-CfI) Woolwich, South London Healthcare NHS Trust St George’s Healthcare NHS Trust New centres joining the collaboration: These centres will be in chic2013 dataset: Wolverhampton - The Royal Wolverhampton NHS Trust Coventry - University Hospitals Coventry and Warwickshire NHS Trust Chertsey – Ashford and St Peter’s Hospitals NHS Foundation Trust Future: Newham University Hospital, Barts Health NHS Trust, London St. Thomas’ Hospital, London - Guy’s and St Thomas’ NHS Foundation Trust

Inclusion criteria Patients: aged > 16 years and seen at any of the centres since 1/1/1996 Clinics: electronic data are already available able to provide data on an annual basis

Funding Study funded by the MRC since 2001 Funding provides: some database programming support project co-ordination statistical support limited funding for clinics for provision of data The database is physically located at MRC CTU – centrally located and ‘independent’ of all clinical centres The project co-ordinator and principal investigator are based at UCL (Royal Free campus)

Study management Steering committee meets every 3-6 months with representatives from: - each clinical centre - the coordinating centre - the UK Resistance Database - the patient community Specific sub-groups: - data management - viral hepatitis co-infection - pregnancy - HIV and ageing - renal outcomes

Data protection policy Policy drafted by a sub-group with input from experts in health informatics. Data are submitted by secure web-based transfer (FTP), plus encryption. Database access is restricted and monitored. Datasets released for research analyses are approved by the steering committee, are anonymised, and only include necessary data. Personnel with access to the data are made aware of data confidentiality requirements.

Processes Datasets and formats agreed upon by all centres Data sent to coordinator by centres Data checked for consistency Data entered into main database; error and logical checks performed Datasets and formats agreed upon by all centres Data from all centres merged and possible duplicates identified Final dataset distributed for analysis Errors checked and corrected on source and submitted dataset Results fed back to clinics and data managers Subset of records audited

Datasets Demographics (patient, centre, ethnicity, risk group, first and last attendance) Clinical events - AIDS - serious non-AIDS - death Antiretroviral therapy Hepatitis - A/B/C tests - clinical data Laboratory-defined toxicities Adherence Prophylaxis (PCP) (No longer collected) CD4 viral loads HLA-B*5701 Attendance ? future data items Hepatitis, Adherence and Toxicity data collected from 2004 onwards HLAB57 and Attendance data collected form 2009 onwards Hepatitis additional data collected in 2012-14, from 2006 onwards, includes hep treatment, liver scans, clinical data

Data quality checks missing data items (demographics, drug names, CD4/CD8 counts, HIV RNA) duplicate patients within same centre duplicate laboratory measurements or AIDS events undetectable viral load at start of treatment CD4 or CD8 counts of zero inconsistent data and dates (e.g. HIV+ve date before HIV-ve date, any odd or future dates) overlapping drug start/stop dates All queries are investigated and both CHIC and clinic databases are updated with corrected information

De-duplication process Individuals may have attended more than one clinical centre. Potential matches identified by matching date of birth and soundex; other demographic variables are used to determine whether potential matches are definite or indeterminate, e.g. - HIV+ve dates in same calendar year - dates of death within 1 month - transferred to/from same centre - first/last seen dates are consistent - same country of birth (non-UK only) Once duplicate patients have been identified, data from individual records are combined.

Improving death data Many patients do not ‘reappear’ at their clinics for long periods of time; some of these may have left the country and/or may have died. UK CHIC records are matched to records held at the PHE (which include death data from the Office of National Statistics) Matches are sent to centres to check that no evidence exists that the patient is still alive; when confirmed, the database is updated. From 2010, ONS data not available at the MRC CTU. Individual studies now have to apply for access to ONS data. Through the DHICE project, death data could be supplemented from ONS data obtained by the HPA (HPA has access to ONS data). HPA will have ONS data for deaths up to 65 years of age, extra data are beneficial as life expectancy with HIV is increasing. Extra death info also obtained from CoDe forms. Will try and incorporate into CHIC more info on causes of death – recorded in ONS data from June 2001 onwards, and from CoDe forms (2006 onwards).

Audit of data 1% of records from each centre are audited. Each record ‘recreated’ using data obtained from clinical notes and compared with information stored on database (not CD4 or viral load). Exact match required for demographic data, and date to within 1 month for dates of starting ART and AIDS events. Demographic data generally reasonable (a few problems with ethnicity and country of birth); some discrepancies in AIDS events or dates. Some AIDS events and ARV drugs found in notes but not database and vice versa.

Link to UK HIV Drug Resistance Database UK CHIC is linked with UK Collaborative Group on HIV Drug Resistance, set up in 2001 to collect information on routinely performed resistance tests in the UK. Resistance test data (sequences) are collected. There is substantial overlap of patients in the two databases so clinical information is shared. Results of over 106,000 resistance tests relating to 66,100 patients are stored on the database – 24,700 patients have linked clinical data in the UK CHIC study (data to end of 2012). Resistance tests for CHIC patients – Number of patients + Resist test that are in CHIC = 24,700/50,785 = (48.6%) Anna Tostevin currently doing data linkage 2014

Key findings

Characteristics of cohort n % Total number of patients 50785 100.0 Sex: Male Female 36645 14140 72.2 27.8 Risk group: MSM IDU 24799 1710 48.8 3.4 Heterosexual Other/not known 18950 5326 37.3 10.5 Ethnicity: White 26517 52.2 Black African 14107 Black Other 2686 5.3 Other/Not known 7475 14.7 Deaths 4639 9.1 CHIC 2013 dataset

Study outputs

Collaborations TDM Registry University of Liverpool Collaborative HIV Paediatric Study (CHIPS) European COHERE collaboration UK HIV Drug Resistance database National Study of HIV in Pregnancy and Childhood (NSHPC) TDM Therapeutic Drug Monitoring NSHPC (Pat Tookey) and London HIV perinatal research group Methodology groups Bristol- Jonathan Sterne, Margaret May Statistical research/ methodology groups Public Health England (surveillance)

Acknowledgements Steering Committee: Jonathan Ainsworth, Sris Allan, Jane Anderson, Abdel Babiker, David Chadwick, Valerie Delpech, David Dunn, Martin Fisher, Brian Gazzard, Richard Gilson, Mark Gompels, Phillip Hay, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clifford Leen, Fabiola Martin, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Frank Post, Jillian Pritchard, Caroline Sabin (PI), Memory Sachikonye, Achim Schwenk, Anjum Tariq, John Walsh. Central Co-ordination: Teresa Hill, Sophie Jose, Andrew Phillips, Caroline Sabin, Alicia Thornton, Susie Huntington (UCL); David Dunn, Adam Glabay (Medical Research Council Clinical Trials Unit [MRC CTU at UCL]) Participating sites: Brighton and Sussex University Hospitals NHS Trust (M Fisher, N Perry, S Tilbury, E Youssef, D Churchill); Chelsea and Westminster Hospital NHS Foundation Trust, London (B Gazzard, M Nelson, R Everett, D Asboe, S Mandalia); King’s College Hospital NHS Foundation Trust, London (F Post, H Korat, C Taylor, Z Gleisner, F Ibrahim, L Campbell); Mortimer Market Centre, University College London (R Gilson, N Brima, I Williams); Royal Free NHS Foundation Trust/University College London (M Johnson, M Youle, F Lampe, C Smith, R Tsintas, C Chaloner, S Hutchinson, C Sabin, A Phillips, T Hill, S Jose, A Thornton, S Huntington); Imperial College Healthcare NHS Trust, London (J Walsh, N Mackie, A Winston, J Weber, F Ramzan, M Carder); Barts and The London NHS Trust, London (C Orkin, J Lynch, J Hand, C de Souza); Homerton University Hospital NHS Trust, London (J Anderson, S Munshi); North Middlesex University Hospital NHS Trust, London (J Ainsworth, A Schwenk, S Miller, C Wood); The Lothian University Hospitals NHS Trust, Edinburgh (C Leen, A Wilson, S Morris); North Bristol NHS Trust (M Gompels, S Allan); Leicester, University Hospitals of Leicester NHS Trust (A Palfreeman, K Memon, A Lewszuk); Middlesbrough, South Tees Hospitals NHS Foundation Trust (D Chadwick, E Cope, J Gibson); Woolwich, Lewisham and Greenwich NHS Trust (S Kegg, P Main, Dr Mitchell, Dr Hunter), St George’s Healthcare NHS Trust (P Hay, M Dhillon); York Teaching Hospital NHS Foundation Trust (F Martin, S Russell-Sharpe); Coventry, University Hospitals Coventry and Warwickshire NHS Trust (S Allan, A Harte, S Clay); Wolverhampton, The Royal Wolverhampton Hospitals NHS Trust (A Tariq, H Spencer, R Jones); Chertsey, Ashford and St Peter’s Hospitals NHS Foundation Trust (J Pritchard, S Cumming, C Atkinson); Public Health England, London (V Delpech); UK Community Advisory Board (M Sachikonye). List is appropriate for the chic2013 data submission and preparation, so may not include the latest staff at centres. Funding: UK CHIC is funded by the UK Medical Research Council

www.ukchic.org.uk